Common use of Sunesis Core Technology Clause in Contracts

Sunesis Core Technology. Sunesis No. Serial No. Title Status SU-100 US 09/105,372 Methods for Rapidly Identifying Small Organic Molecule Ligands for Binding to Biological Target Molecules Granted U.S. Patent No. 6,335,155 SU-100 D1C1 US 10/043,833 Methods for Rapidly Identifying Small Organic Molecule Ligands for Binding to Biological Target Molecules Granted as US Patent No. 6,811,966 { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THE NOTATION “[RESERVED]” IS ORIGINAL, IS CURRENTLY IN THE DOCUMENT AND DOES NOT REFLECT INFORMATION REDACTED PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. EXHIBIT 1.41 { * } { * } = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THE NOTATION “[RESERVED]” IS ORIGINAL, IS CURRENTLY IN THE DOCUMENT AND DOES NOT REFLECT INFORMATION REDACTED PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. EXHIBIT 2.7.1 Phase II Drug Compounds { * } { * } = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THE NOTATION “[RESERVED]” IS ORIGINAL, IS CURRENTLY IN THE DOCUMENT AND DOES NOT REFLECT INFORMATION REDACTED PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. EXHIBIT 3.5 Reverted Products

Sunesis Core Technology. Sunesis No. Serial No. Title Status SU-100 US 09/105,372 Methods for Rapidly Identifying Small Organic Molecule Ligands for Binding to Biological Target Molecules Granted U.S. Patent No. 6,335,155 SU-100 D1C1 US 10/043,833 Methods for Rapidly Identifying Small Organic Molecule Ligands for Binding to Biological Target Molecules Granted as US Patent No. 6,811,966 { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTCertain confidential information contained in this document, MARKED BY BRACKETSmarked by brackets, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, AS AMENDEDas amended. THE NOTATION “[RESERVED]” IS ORIGINAL, IS CURRENTLY IN THE DOCUMENT AND DOES NOT REFLECT INFORMATION REDACTED PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. EXECUTION VERSION EXHIBIT 1.41 1.72 BTK Assays { * } { * } = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTCertain confidential information contained in this document, MARKED BY BRACKETSmarked by brackets, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, AS AMENDED. THE NOTATION “[RESERVED]” IS ORIGINAL, IS CURRENTLY IN THE DOCUMENT AND DOES NOT REFLECT INFORMATION REDACTED PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. EXHIBIT 2.7.1 Phase II Drug Compounds { * } { * } = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THE NOTATION “[RESERVED]” IS ORIGINAL, IS CURRENTLY IN THE DOCUMENT AND DOES NOT REFLECT INFORMATION REDACTED PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. EXHIBIT 3.5 Reverted Productsas amended.

Sunesis Core Technology. Sunesis No. Serial No. Title Status SU-100 US 09/105,372 Methods for Rapidly Identifying Small Organic Molecule Ligands for Binding to Biological Target Molecules Granted U.S. Patent No. 6,335,155 SU-100 D1C1 US 10/043,833 Methods for Rapidly Identifying Small Organic Molecule Ligands for Binding to Biological Target Molecules Granted as US Patent No. 6,811,966 { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTCertain confidential information contained in this document, MARKED BY BRACKETSmarked by brackets, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, AS AMENDEDas amended. THE NOTATION “[RESERVED]” IS ORIGINAL, IS CURRENTLY IN THE DOCUMENT AND DOES NOT REFLECT INFORMATION REDACTED PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. EXECUTION VERSION EXHIBIT 1.41 1.72 BTK Assays { * } {2 pages omitted} -57- { * } = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTCertain confidential information contained in this document, MARKED BY BRACKETSmarked by brackets, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, AS AMENDED. THE NOTATION “[RESERVED]” IS ORIGINAL, IS CURRENTLY IN THE DOCUMENT AND DOES NOT REFLECT INFORMATION REDACTED PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDas amended. EXHIBIT 2.7.1 Phase II Drug Compounds { * } { * } = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THE NOTATION “[RESERVED]” IS ORIGINAL, IS CURRENTLY IN THE DOCUMENT AND DOES NOT REFLECT INFORMATION REDACTED PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. EXHIBIT 3.5 Reverted Products2.7.1